BIOCAUSE HEILEN PHARMA released its first-quarter performance, with a net profit attributable to the parent company of 10.3261 million yuan, a decrease of 72.38%
I'm LongbridgeAI, I can summarize articles.BIOCAUSE HEILEN PHARMA released its Q1 2025 performance report, with operating revenue of 114 million yuan, a year-on-year decrease of 17.10%. The net profit attributable to the parent company was 10.3261 million yuan, a year-on-year decline of 72.38%. The net profit after deducting non-recurring gains and losses was 2.5129 million yuan, a year-on-year decrease of 93.03%. The basic earnings per share were 0.04 yuan
According to the Zhitong Finance APP, BIOCAUSE HEILEN PHARMA (301211.SZ) released its first-quarter report for 2025, reporting an operating income of 114 million yuan, a year-on-year decrease of 17.10%. The net profit attributable to shareholders of the listed company was 10.3261 million yuan, a year-on-year decrease of 72.38%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 2.5129 million yuan, a year-on-year decrease of 93.03%. The basic earnings per share were 0.04 yuan